Other multiplicity-controlled endpoints
atopic, Skin Pain, non-atopic
ATOPIC
Additional multiplicity-controlled endpoints in both trials included changes from baseline in DLQI, Skin Pain NRS and HADS at week 24 and, in PRIME2 only, change in Sleep NRS at week 24 (Extended Data Table Efficacy outcomes were similar between atopic and non-atopic patients as well as those who used TCS/TCI throughout the trial compared to those who did not (Extended Data Tables 